The cohort comprised patients over 20 years old who were newly treated with glucose-lowering drugs between 1 January 2013 and 31 December 2021, and followed until 30 September 2022
During this phase, the liver attaches a glutathione molecule to a toxin or a spent hormone to make it water-soluble
New Safety Signal: Dysesthesia The TRIUMPH-4 trial identified a previously unreported side effect called dysesthesia an abnormal sensation of touch where normal sensations feel unusual, uncomfortable, or mildly painful (like tingling, numbness, or "pins and needles")
Rapid nutrient delivery via oral dissolving films
Researchers using GHK-Cu in populations with impaired renal function should consider reducing dose frequency to every 72 hours instead of every 48 hours to avoid accumulation of copper, which is also renally excreted and can contribute to oxidative stress at excessive levels
This timeline is slightly slower than tirzepatide at equivalent points in the dose escalation, but the endpoint results at maximum tolerated doses are closer than many people expect